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Background: In Japan, combination therapy with high doses of antipsychotic drugs is common, but as a
consequence, many patients with schizophrenia report extrapyramidal and autonomic nervous system side effects.
To resolve this, we proposed a method of safety correction of high dose antipsychotic polypharmacy (the SCAP method),
in which the initial total dose of all antipsychotic drugs is calculated and converted to a chlorpromazine equivalent
(expressed as milligrams of chlorpromazine, mg CP). The doses of low-potency antipsychotic drugs are then reduced
by≤ 25 mg CP/week, and the doses of high-potency antipsychotics are decreased at a rate of ≤50 mg CP/week.
Although a randomized, case-controlled comparative study has demonstrated the safety of this method, the number of
participants was relatively small and its results required further validation. In this study of the SCAP method, we aimed to
substantially increase the number of participants.
Methods/design: The participants were in- or outpatients treated with two or more antipsychotics at doses of
500–1,500 mg CP/day. Consenting participants were randomized into control and dose reduction groups. In the control
group, patients continued with their normal regimen for 3 months without a dose change before undergoing the SCAP
protocol. The dose reduction group followed the SCAP strategy over 3–6 months with a subsequent 3-month follow-up
period. Outcome measures were measured at baseline and then at 3-month intervals, and included clinical symptoms
measured on the Manchester scale, the extent of extrapyramidal and autonomic side effects, and quality of life using the
Euro QOL scale. We also measured blood drug concentrations and drug efficacy-associated biochemical parameters. The
Brief Assessment of Cognition in Schizophrenia, Japanese version, was also undertaken in centers where it was available.
Discussion: The safety and efficacy of the SCAP method required further validation in a large randomized trial. The
design of this study aimed to address some of the limitations of the previous case-controlled study, to build a more
robust evidence base to assist clinicians in their efforts to reduce potentially harmful polypharmacy in this vulnerable
group of patients.
Trial registration: UMIN Clinical Trials Registry 000004511.
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Antipsychotics should be used as monotherapy, but in
many countries patients may be prescribed two or more
antipsychotic drugs as combination therapy [1]. The use
of more than one antipsychotic drug is particularly
prevalent in East Asia [2], and polypharmacy with high
dose antipsychotics is relatively common in Japan [3].* Correspondence: sukegawt@tottori-iryo.hosp.go.jp
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unless otherwise stated.As antipsychotic polypharmacy may cause adverse drug
reactions [4], these drugs should be used as monotherapy
at the minimum necessary dose whenever possible. After a
warning on the inappropriate use of antipsychotics was
issued in Japan, the situation improved to some extent [5].
Nonetheless, dose reduction may be challenging in patients
receiving high dose antipsychotic polypharmacy. We have
previously proposed a protocol for the gradual reduction of
antipsychotic drug dose for patients on high doses of more
than one agent [6].tral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Sukegawa et al. BMC Psychiatry 2014, 14:103 Page 2 of 6
http://www.biomedcentral.com/1471-244X/14/103We examined the safety and efficacy of this method in a
randomized, case-controlled comparative study (the Reduc-
tion and Simplification [RAS] study) [7]; however, the num-
ber of participants was small and the results required
further validation. To support the reliability of this method,
we conducted a randomized, case-controlled comparative
study (the “Safety Correction of high dose Antipsychotic
Polypharmacy [SCAP] study). This article describes the
methods used.
The SCAP protocol
The chlorpromazine equivalent dose (mg) is expressed as
“mg CP”. To convert the doses of various antipsychotics to
chlorpromazine equivalent doses, we used the calculation
table prepared by Inagaki and colleagues, which is routinely
adopted in Japan [8]. Antipsychotics of which the doses
equivalent to 100 mg of chlorpromazine are 10 mg or less
were regarded as high-potency drugs, and those of which
the doses equivalent to 100 mg of chlorpromazine exceed
10 mg were regarded as low-potency drugs.
Tanabe [9] and Murasugi et al. [10] have published arti-
cles reporting both successful and unsuccessful strategies
for reducing the doses of antipsychotics, including the
extent of dose reduction reported as a chlorpromazine
equivalent dose, and the dose reduction period. On the
basis of these studies, we calculated the rate of dose reduc-
tion in those that succeeded in reducing the dose and
those who failed. In participants who failed to reduce the
dose, the rate of reduction was approximately 100 mg CP
per week in patients initially taking 2,000 mg CP daily
(Table 1). In those in whom the dose was reduced success-
fully, the rate of reduction was about 40 mg CP per week
in patients in whom the starting dose was 1,400 mg CP.
As such, the maximum acceptable reduction speed may
be 50 mg CP or less per week. Low-potency antipsy-
chotics’ different affinity for dopaminergic D2 receptors,
acetylcholine receptors, histamine receptors and serotoninTable 1 Rates of reduction used in previous research
Tanabe’s research [9]
Group Mean dose before reduction Red
Successful 1,372 mg CP 40.
Unsuccessful 1,832 mg CP 95.
Murasugi’s research [10]
Group Mean dose before reduction Red
Successful 1,581 mg CP 43.
Unsuccessful 2,389 mg CP 97.
Combination of both studies
Group Mean dose before reduction Red
Successful 1,397 mg CP 40.
Unsuccessful 2, 006 mgCP 96.
Abbreviations: GAF global assessment of functioning in DSM-4-TR; SOI severity of illnreceptors compared with high-potency antipsychotics re-
quire doses 10–100 times higher than those of high-
potency antipsychotics. When decreasing the doses of
drugs with potent anticholinergic actions, anticholinergic
withdrawal symptoms such as insomnia, anxiety and rest-
lessness may occur. To take this into account, the rate of
reduction of low-potency antipsychotics was established
as being half that of high-potency antipsychotics, namely
25 mg or less per week. Furthermore, it was established
that the total amount of drug that can be subtracted from
the daily dose, that is the maximum acceptable amount of
reduction, was twice the value of the maximum acceptable
reduction rate. This amount was applied to each drug, and
the actual dose of the drug (not a chlorpromazine equiva-
lent dose) was calculated as shown in Tables 2 and 3 [11].
The SCAP study was conducted in accordance with the
maximum acceptable amount of dose reduction and max-
imum acceptable reduction rate based on these tables.
The chlorpromazine equivalent dose was adopted as a
means of calculating the rate of dose reduction for the
following reasons. It is known that the potency of anti-
psychotics is proportional to their binding capacity to
dopamine D2 receptors. In patients who have taken very
high dose antipsychotics over a long period, D2 receptor
expression may have been upregulated to compensate
for D2 antagonism. Recurrent psychiatric symptoms in-
duced by decreasing the doses of antipsychotics are some-
times called “dopamine supersensitivity psychosis” [12].
Therefore, we adopted the chlorpromazine equivalent
dose, which represents the potency of the antipsychotic, to
allow us to evaluate the degree of reduction in anti-
D2activity caused by dose reduction.
The rate of reduction was expressed as an absolute
value, not as a proportion of the total chlorpromazine
equivalent dose of the antipsychotic. Intuitively, a method
of decreasing the dose by a small proportion (for example
1%) of the total dose per week may be appropriate;uction speed GAF SOI n
4 mg CP/week 34.1 4.5 37
4 mg CP/week 29.8 4.8 11
uction speed GAF SOI n
0 mg CP/week 35.2 4.8 5
4 mg CP/week 44.0 4.5 5
uction speed GAF SOI n
7 mg/week 33.5 4.5 42
0 mg/week 34.2 4.7 16
ess; n number of patients.









Perphenazine PZC, others 5 10
Perospirone Lullan 4 8
Trifluoperazine Trifluoperazine 2.5 5
Nemonapride Emilace 2.25 4.5
Aripiprazole Abilify 2 4
Blonanserin Lonasen 2 4
Pimozide OLAP 2 4
Olanzapine Zyprexa 1.25 2.5




Fluphenazine Flumezin 1 2
Timiperone Tolopelone 0.65 1.3




†Maximum reduction rate represents the maximum acceptable reduction per week.
‡Maximum reduction represents the maximum amount of reduction at a time.
After maximum reduction, subsequent reduction is performed after a
minimum 2-week observation period.
(Cited and partially modified from Sukegawa [11]).










Sultopride Barnetil 50 100







Carpiprammine Defecton 25 50




Quetiapine Seroquel 16.5 33
Clocapramine Clofekton 10 20
Mosapramine Cremin 8.25 16.5
Propericiazine Neuleptil 5 10
Prochlorperazine Novamin 3.75 7.5
Moperone Luvatren 3.125 6.25
†Maximum reduction rate represents the maximum acceptable reduction per week.
‡Maximum reduction represents the maximum amount of reduction at a time.
After maximum reduction, subsequent reduction is performed after a minimum
2-week observation period.
(Cited and partially modified from Sukegawa [11]).
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of antipsychotics is high, D2 receptors may become super-
sensitive to compensate for the D2-mediated actions
inhibited by the antipsychotics. Therefore, when decreas-
ing the dose of an antipsychotic, dopamine supersensitivity
psychosis may occur if the chlorpromazine equivalent
dose of the antipsychotic administered at the start of dose
reduction is high. When the dose is higher, the dose must
be weaned at a reduced rate. To achieve this, the reduc-
tion speed should be considered as an absolute value, not
as a proportion of the total dose.
Gradually reducing the dose of antipsychotics in this way
may be a useful strategy for rationalizing high dose anti-
psychotic regimes. A pilot randomized study involving 39
patients at 10 institutions was completed in 2007 (the RAS
study) [7]. The participants were patients with schizophre-
nia who had been hospitalized for 1 year or more, treated
with three or more antipsychotics at a dose of 1,500 mg
CP/day or higher, and were capable of understanding the
explanatory document and giving informed consent. In the
reduction and simplification group, the 6-month reduction
and simplification protocol was completed before a 3-
month follow-up period, targeting reduction by 500 mg CP
per day or more and the number of antipsychotics to one
or two. In the reduction and simplification group (which
consisted of 19 patients taking a mean of 3.7antipsychotic
drugs at a mean dose of 2,067 mg CP at the time of enroll-
ment), the mean dose reduction was 674 mg CP, and the
mean reduction in the number of drugs was 1.0. Eleven pa-
tients succeeded in reducing their dose by 500 mg CP or
more. However, the number of drugs taken could be re-
duced to one or two in only five patients. Hallucinations
or delusions recurred in four patients, which were suc-
cessfully treated by dose escalation in all cases. Two pa-
tients dropped out because of transfer to another hospital
or the aggravation of physical symptoms. Three patients
violated the protocol, one of whom experienced recur-
rence of hallucinations and delusions. Overall, 11 (79%) of
the 14 patients excluding those who deviated from the
protocol or dropped out succeeded in reducing their dose
by 500 mg or more. In the control group (which consisted
of 20 patients taking a mean of 3.5antipsychotic drugs at a
mean dose of 2,143 mg CP at the time of enrollment),
three patients dropped out owing to the aggravation of
physical symptoms, extrapyramidal adverse drug reac-
tions, or hallucinations or delusions, and two violated the
protocol. Hallucinations or delusions were reported by
four of the 19 patients in the reduction and simplification
group and one of the 20 patients in the control group, but
this difference was not statistically significant. Comparison
of the clinical characteristics of the reduction and simplifi-
cation and control groups at the time of enrollment found
no significant differences other than a higher proportion
of women in the reduction and simplification group. After
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promazine equivalent dose were significantly lower in the
reduction and simplification group. No significant differ-
ences were noted in the evaluation or test items between
the groups. When the group who achieved dose reduc-
tions of 500 mg or more (11 patients) was compared with
the control group excluding those who violated the study
protocol or dropped out (15 patients), the incidence of
autonomic adverse drug reactions (particularly nausea and
vomiting) had significantly reduced by the ninth month. A
limitation of the RAS study was that there were only 39
participants. We undertook the SCAP study to confirm
the usefulness of the SCAP method in a larger cohort of
patients with schizophrenia.
Methods
This was an open-label, multicenter, randomized study
conducted between November 2010 and March 2012. The
recurrence and dropout rates during the study period, as
well as changes in psychiatric symptoms, side effects of
the extrapyramidal and autonomic nervous systems, and
quality of life, were compared between the dose reduction
and control groups. The study was conducted in accord-
ance with the Declaration of Helsinki and Good Clinical
Practice. The study protocol was also examined and
approved by the ethics review board of each center, and by
the Ethics Review Board of Fujita Health University for ap-
plications from those centers without their own panel.
The participants were inpatients or outpatients, aged
20 years or older, diagnosed with schizophrenia accord-
ing to the Diagnostic and Statistical Manual of Mental
Disorder, 4th edition text version (DSM-IV-TR) [13],
who were taking two or more antipsychotics at doses of
500–1500 mg CP/day. Written informed consent was
obtained from all participants. Each participant was
assigned to the dose reduction or control group accord-
ing to a randomization protocol administered by Fujita
Health University. A total of 163 patients were ultim-
ately enrolled; 101 were assigned to the dose reduction
group and 62 to the control group.
In the dose reduction group, the dose was decreased to
80% or less than the initial dose over 3–6 months according
to the SCAP method. Participants were subsequently
followed up for a further 3 months. Clinical symptoms were
evaluated using the Manchester scale [14], the extent of
extrapyramidal side effects using the Drug-induced Extra-
pyramidal Symptoms Scale (DIEPSS) [15], autonomic side
effects using the Udvalg for Kliniske Undersogelser11-item
scale (UKU-11) [16], and quality of life using the Euro
QOL scale [17]. In addition, measurement of blood drug
concentrations and drug efficacy-associated biochemical
parameters were performed. The Brief Assessment of Cog-
nition in Schizophrenia, Japanese version (BACS-J) [18]
was also performed in centers where it was available.According to the SCAP method, the doses of high-
potency drugs were reduced at a rate of 50 mg CP per
week or less, and those of low-potency drugs at a rate of
25 mg CP per week or less [6]. In the control group, the
doses of antipsychotics were not changed for 3 months if
clinically feasible, and then doses were reduced according
to the same protocol.
Sample size calculation and statistical techniques
Sample size calculation was undertaken to allow detection
of non-inferiority of the dose reduction group compared
with the control group on the basis of the primary out-
come measure based on a binary set-up repeated measure-
ment linear mixed model using G*power3.1.5 (http://
www.gpower.hhu.de/). For repeated measures analysis of
variance (ANOVA) between factors, if the α error was as-
sumed to be 0.025 (to analyze multiple scales), statistical
power was 0.8, non-inferiority margin of Cohen’s d was
0.2 (it was predicted that the difference was smaller than
moderate), the correlation among repeated measures was
0.5 and the number of measurements was six, then the
size of the cohort was determined as 142. On this basis,
we aimed to enroll 72 participants to each group. Data
were finalized on January 31, 2013. Missing values
were supplemented using the mixed model repeated
measures (MMRM) method and a t-test was performed
to examine differences in the means of each outcome
measure between the groups. All analyses were under-
taken using the Japanese version of SPSS (version 21.0.
IBM, Tokyo, Japan).
Discussion
The doses of antipsychotics were reduced in the RAS
study and the SCAP study using the same method, but
the two studies are different. The RAS study had been
completed by December 2007, but the SCAP study did
not commence until November 2010. The main limita-
tion of the RAS study was its small sample size, but
there were additional problems with the study design.
The SCAP study aimed to enroll a larger number of par-
ticipants to address these limitations.
For the convenience of our investigators, we stipulated
the rate of dose reduction in the SCAP study. In the RAS
study, participating psychiatrists had calculated the rate of
dose reduction by themselves based on SCAP criteria.
Criteria for enrollment in the SCAP study were as fol-
lows: both inpatients and outpatients were considered ac-
ceptable, treatment with two or more antipsychotics at
doses of 500–1,500 mg CP, and a follow-up period of
3 months in the control group. Practically, it can be diffi-
cult to obtain written informed consent from patients tak-
ing antipsychotics at a dose in excess of 1,500 mg CP.
Furthermore, some patients refuse to participate, claiming
that they did not wish to be assigned to the control group
Sukegawa et al. BMC Psychiatry 2014, 14:103 Page 5 of 6
http://www.biomedcentral.com/1471-244X/14/103and thus have to remain on an elevated dose for an ex-
tended period despite their agreement to participate in a
study regarding dose reduction. We therefore established
a shorter follow-up period for those in the control group,
despite the fact that this might influence our findings.
These elements of the SCAP study design differentiate it
from the RAS study, in which only inpatients were en-
rolled, participants had been treated with more than three
antipsychotics at doses in excess of 1,500 mg CP, and the
follow-up period was 9 months in both the dose reduction
and control groups.
The missing data in the control group are a conse-
quence of our study protocol. The missing data were
regarded as “Missing Completely At Random (MCAR)”
or at least “Missing At Random (MAR)”. Therefore, the
MMRM was thought to be most suitable for supplemen-
tation of the missing data in this study [19].
Many psychiatrists in Japan understand that very high
doses of antipsychotics should be avoided, but also that
overly rapid dose reduction may result in withdrawal
symptoms mediated by dopaminergic D2, cholinergic or
other receptors. These symptoms may be misdiagnosed as
relapse and consequently dose reduction may be aban-
doned. If our findings suggest that the SCAP method is a
useful means of reducing the dose of antipsychotic drugs
and rationalizing antipsychotic polypharmacy, the strategy
might help the prescription of antipsychotic drugs in Japan
meet international standards.
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